NASDAQ:BYSI BeyondSpring (BYSI) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free BYSI Stock Alerts $2.13 -0.14 (-6.17%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$2.10▼$2.3850-Day Range$1.07▼$3.6352-Week Range$0.65▼$4.00Volume33,800 shsAverage Volume183,357 shsMarket Capitalization$82.90 millionP/E RatioN/ADividend YieldN/APrice Target$1.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BeyondSpring alerts: Email Address BeyondSpring MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside41.3% Downside$1.25 Price TargetShort InterestBearish10.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.00 out of 5 starsMedical Sector916th out of 916 stocksPharmaceutical Preparations Industry416th out of 416 stocks 0.0 Analyst's Opinion Amount of Analyst CoverageBeyondSpring has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.07% of the float of BeyondSpring has been sold short.Short Interest Ratio / Days to CoverBeyondSpring has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in BeyondSpring has recently increased by 0.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBeyondSpring does not currently pay a dividend.Dividend GrowthBeyondSpring does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BYSI. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for BYSI on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BeyondSpring insiders have not sold or bought any company stock.Percentage Held by Insiders29.31% of the stock of BeyondSpring is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.29% of the stock of BeyondSpring is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About BeyondSpring Stock (NASDAQ:BYSI)BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Read More BYSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BYSI Stock News HeadlinesMarch 25, 2024 | globenewswire.comBeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerMarch 14, 2024 | finance.yahoo.comBYSI Oct 2024 7.500 callApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 7, 2024 | finance.yahoo.comBYSI Mar 2024 7.500 callMarch 6, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.04%March 6, 2024 | finance.yahoo.comRetail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewardedMarch 5, 2024 | finance.yahoo.comBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsFebruary 22, 2024 | uk.finance.yahoo.comBeyondSpring Inc. (BYSI) stock historical prices & data – Yahoo FinanceApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.January 18, 2024 | morningstar.comBeyondSpring Inc BYSIJanuary 18, 2024 | finance.yahoo.comBeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KJanuary 11, 2024 | msn.comBeyondSpring gets Nasdaq delinquency noticeDecember 27, 2023 | benzinga.comBeyondSpring Stock (NASDAQ:BYSI) Insider TradesDecember 27, 2023 | benzinga.comBeyondSpring Stock (NASDAQ:BYSI) Dividends: History, Yield and DatesDecember 26, 2023 | seekingalpha.comOncternal slips after early data for lymphoma therapyDecember 20, 2023 | msn.comPassage Bio stock climbs 9% on dementia study, program updateOctober 31, 2023 | msn.comBeyondSpring regains compliance with Nasdaq minimum bid price ruleOctober 31, 2023 | finance.yahoo.comBeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsOctober 30, 2023 | finance.yahoo.comBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 26, 2023 | markets.businessinsider.comSEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumOctober 23, 2023 | stockhouse.comSEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of DirectorsOctober 5, 2023 | finanznachrichten.deBeyondSpring, Inc.: BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsSeptember 27, 2023 | benzinga.comBeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual MeetingSeptember 27, 2023 | finance.yahoo.comBeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual MeetingSeptember 7, 2023 | finance.yahoo.comBeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare ConferenceJune 20, 2023 | finance.yahoo.comSEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of DirectorsJune 7, 2023 | finance.yahoo.comBeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTSee More Headlines Receive BYSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/29/2021Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BYSI CUSIPN/A CIK1677940 Webwww.beyondspringpharma.com Phone(646) 305-6387Fax1-646-882-4228Employees73Year FoundedN/APrice Target and Rating Average Stock Price Target$1.25 High Stock Price Target$1.25 Low Stock Price Target$1.25 Potential Upside/Downside-41.3%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.35 million Price / Sales61.41 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-5.92Miscellaneous Outstanding Shares38,920,000Free Float27,515,000Market Cap$82.90 million OptionableOptionable Beta0.15 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Lan Huang Ph.D. (Age 53)Co-Founder, Chairman & CEO Mr. Linqing JiaCo-FounderDr. June Lu Ph.D.Chief Scientific OfficerStephen KilmerHead of Investor RelationsMr. Gregg RussoSenior Vice President of Human ResourcesKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTBioXcel TherapeuticsNASDAQ:BTAIAclaris TherapeuticsNASDAQ:ACRSSELLAS Life Sciences GroupNASDAQ:SLSAssertioNASDAQ:ASRTView All CompetitorsInstitutional OwnershipDecheng Capital LLCBought 4,958,143 shares on 2/12/2024Ownership: 12.738%View All Institutional Transactions BYSI Stock Analysis - Frequently Asked Questions What is BeyondSpring's stock price target for 2024? 0 Wall Street research analysts have issued 1 year price targets for BeyondSpring's stock. Their BYSI share price targets range from $1.25 to $1.25. On average, they predict the company's share price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 41.3%. View analysts price targets for BYSI or view top-rated stocks among Wall Street analysts. How have BYSI shares performed in 2024? BeyondSpring's stock was trading at $0.90 at the beginning of 2024. Since then, BYSI shares have increased by 136.7% and is now trading at $2.13. View the best growth stocks for 2024 here. How were BeyondSpring's earnings last quarter? BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.11. The business earned $0.34 million during the quarter, compared to analyst estimates of $0.34 million. What other stocks do shareholders of BeyondSpring own? Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), Dynavax Technologies (DVAX). When did BeyondSpring IPO? BeyondSpring (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO. How do I buy shares of BeyondSpring? Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BYSI) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
